Shanghai Finete Pharmaceutical

Shanghai Finete Pharmaceutical, also known as Vantrus Pharmaceutical, is a clinical-stage biotechnology company based in Shanghai, China, focused on the discovery and development of innovative small molecule therapies for metabolic and chronic liver diseases. The company's research centers on modulating nuclear receptors and other key metabolic pathways to address significant unmet medical needs in hepatology. Its lead candidate, FNT-101, is a potent and selective Farnesoid X receptor (FXR) agonist currently in Phase 2 clinical trials for the treatment of non-alcoholic steatohepatitis (NASH) and primary biliary cholangitis (PBC). Founded by industry veterans with extensive experience in global drug development, the company leverages its proprietary R&D platform to advance a pipeline of next-generation metabolic treatments. Finete aims to provide transformative therapeutic options for patients suffering from chronic liver conditions worldwide.